238 related articles for article (PubMed ID: 27915971)
1. The IAP Protein Family, SMAC Mimetics and Cancer Treatment.
Philchenkov A; Miura K
Crit Rev Oncog; 2016; 21(3-4):185-202. PubMed ID: 27915971
[TBL] [Abstract][Full Text] [Related]
2. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
3. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
[TBL] [Abstract][Full Text] [Related]
4. Promises and Challenges of Smac Mimetics as Cancer Therapeutics.
Fulda S
Clin Cancer Res; 2015 Nov; 21(22):5030-6. PubMed ID: 26567362
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
[TBL] [Abstract][Full Text] [Related]
6. IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development.
Ali R; Singh S; Haq W
Curr Med Chem; 2018; 25(31):3768-3795. PubMed ID: 29532750
[TBL] [Abstract][Full Text] [Related]
7. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
[TBL] [Abstract][Full Text] [Related]
8. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
9. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
Zinngrebe J; Schlichtig F; Kraus JM; Meyer M; Boldrin E; Kestler HA; Meyer LH; Fischer-Posovszky P; Debatin KM
Int J Cancer; 2020 Jun; 146(11):3219-3231. PubMed ID: 31749151
[TBL] [Abstract][Full Text] [Related]
10. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
11. Smac mimetics as new cancer therapeutics.
Chen DJ; Huerta S
Anticancer Drugs; 2009 Sep; 20(8):646-58. PubMed ID: 19550293
[TBL] [Abstract][Full Text] [Related]
12. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
[TBL] [Abstract][Full Text] [Related]
13. Design of small-molecule Smac mimetics as IAP antagonists.
Wang S
Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.
Talbott RL; Borzilleri RM; Chaudhry C; Fargnoli J; Shen H; Fairchild C; Barnhart B; Ortega M; McDonagh TE; Vuppugalla R; Vite GD; Hunt JT; Gottardis M; Naglich JG
Exp Cell Res; 2015 Nov; 338(2):251-60. PubMed ID: 26302264
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
Amaravadi RK; Schilder RJ; Martin LP; Levin M; Graham MA; Weng DE; Adjei AA
Mol Cancer Ther; 2015 Nov; 14(11):2569-75. PubMed ID: 26333381
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Singh T; Neal A; Dibernardo G; Raheseparian N; Moatamed NA; Memarzadeh S
Int J Oncol; 2022 Mar; 60(3):. PubMed ID: 35191515
[TBL] [Abstract][Full Text] [Related]
17. Smac mimetics as IAP antagonists.
Fulda S
Semin Cell Dev Biol; 2015 Mar; 39():132-8. PubMed ID: 25550219
[TBL] [Abstract][Full Text] [Related]
18. Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity.
Sun H; Liu L; Lu J; Bai L; Li X; Nikolovska-Coleska Z; McEachern D; Yang CY; Qiu S; Yi H; Sun D; Wang S
J Med Chem; 2011 May; 54(9):3306-18. PubMed ID: 21462933
[TBL] [Abstract][Full Text] [Related]
19. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
Zhu H; Li Y; Liu Y; Han B
ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
[TBL] [Abstract][Full Text] [Related]
20. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
